Press-release for stocks in the health services sector related to lone-star-bio

Prices are updated after-hours

sector : Health services tags : Lone-star-bio

save search

Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation
Published: 2024-04-11 (Crawled : 00:00) - biospace.com/
NTRA | News M | $91.47 0.47% 0.47% 810K

Health Services

| -5.18% | O: -0.36% H: 0.0% C: 0.0%
kidney publication study

Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients
Published: 2024-04-08 (Crawled : 13:30) - biospace.com/
NTRA | News M | $91.47 0.47% 0.47% 810K

Health Services

| -5.43% | O: 0.92% H: 0.26% C: -2.26%
test for heart

Guardion Health Sciences Announces Financial Results for the Year Ended December 31, 2023
Published: 2024-03-29 (Crawled : 11:00) - biospace.com/
BEST | $2.12 1.44% 0.0% 3.2K

Transportation

| Email alert Add to watchlist
GHSI | $8.28 -0.75% 7.5K

Health Services

| Email alert Add to watchlist
health year sciences financial results

Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer
Published: 2024-03-18 (Crawled : 12:30) - biospace.com/
NTRA | News M | $91.47 0.47% 0.47% 810K

Health Services

| 2.21% | O: 0.19% H: 1.46% C: 0.48%
cancer trial

Nature Medicine Publishes Two Studies Highlighting Signatera’s Clinical Utility in Patients with Gastrointestinal Malignancies
Published: 2024-01-25 (Crawled : 13:00) - biospace.com/
NTRA | News M | $91.47 0.47% 0.47% 810K

Health Services

| 39.46% | O: 0.59% H: 0.64% C: -2.09%
gastrointestinal

Natera’s Landmark RenaCARE Study Demonstrates Significant Diagnostic and Clinical Utility of Renasight™ in Chronic Kidney Disease
Published: 2023-11-02 (Crawled : 14:00) - biospace.com/
NTRA | News M | $91.47 0.47% 0.47% 810K

Health Services

| 130.54% | O: 2.12% H: 2.57% C: 0.05%
disease diagnostic kidney study

Natera to Report its Third Quarter 2023 Results on November 8
Published: 2023-10-20 (Crawled : 14:00) - biospace.com/
NTRA | News M | $91.47 0.47% 0.47% 810K

Health Services

| 120.85% | O: 0.58% H: 0.0% C: -2.18%
report results

Natera Submits First PMA Module to the FDA for Signatera™
Published: 2023-10-02 (Crawled : 17:00) - biospace.com/
NTRA | News M | $91.47 0.47% 0.47% 810K

Health Services

| 106.78% | O: -1.4% H: 1.38% C: 0.11%
fda

Natera Announces Expanded I-SPY 2 Collaboration to Evaluate Signatera™ for Breast Cancer Patients in the Neoadjuvant Setting
Published: 2023-09-14 (Crawled : 15:00) - biospace.com/
NTRA | News M | $91.47 0.47% 0.47% 810K

Health Services

| 64.86% | O: 0.32% H: 0.41% C: -5.51%
breast cancer collaboration

Natera Announces Pricing of $250 Million Follow-On Offering
Published: 2023-09-07 (Crawled : 09:00) - biospace.com/
MS | News | $93.85 0.1% 0.0% 4.8M

Finance

| 10.64% | O: -0.12% H: 0.0% C: 0.0%
NTRA | News M | $91.47 0.47% 0.47% 810K

Health Services

| 57.76% | O: -2.83% H: 1.12% C: -1.97%
offering

Natera’s Prospera™ Lung Transplant Assessment Test Granted Medicare Coverage
Published: 2023-08-16 (Crawled : 15:00) - biospace.com/
NTRA | News M | $91.47 0.47% 0.47% 810K

Health Services

| 66.91% | O: 0.22% H: 0.27% C: -2.97%
lung test granted

Natera to Participate in Goldman Sachs 44th Annual Global Healthcare Conference
Published: 2023-06-06 (Crawled : 14:00) - biospace.com/
NTRA | News M | $91.47 0.47% 0.47% 810K

Health Services

| 91.62% | O: 0.0% H: 1.57% C: 1.21%
conference global

Natera Announces Data from the ProActive Study that Supports Prospera™ Kidney as an Early Indicator of Transplant Rejection
Published: 2023-06-05 (Crawled : 08:00) - biospace.com/
NTRA | News M | $91.47 0.47% 0.47% 810K

Health Services

| 87.46% | O: -0.59% H: 0.41% C: -1.59%
kidney indicator study

New Natera Data to be Presented at the 2023 ASCO Annual Meeting in 13 Studies Across Multiple Cancer Types
Published: 2023-05-30 (Crawled : 13:00) - biospace.com/
NTRA | News M | $91.47 0.47% 0.47% 810K

Health Services

| 88.19% | O: 0.12% H: 1.17% C: -3.29%
asco cancer meeting

New Publication Demonstrates Utility of Natera’s Signatera™ Test in Melanoma
Published: 2023-03-22 (Crawled : 14:00) - biospace.com/
NTRA | News M | $91.47 0.47% 0.47% 810K

Health Services

| 61.58% | O: 0.0% H: 1.39% C: -1.68%
melanoma test publication

Sanara MedTech Inc. Announces Fourth Quarter and Full Year 2022 Results
Published: 2023-03-20 (Crawled : 22:00) - biospace.com/
SMTI 4 | $32.74 0.43% 0.43% 5.3K

Health Services

| -18.77% | O: 1.22% H: 1.85% C: -1.85%
year results

New Paper Highlights Clinical Utility of Natera’s Renasight™ Test in the Management of Kidney Disease
Published: 2023-02-02 (Crawled : 16:00) - biospace.com/
NTRA | News M | $91.47 0.47% 0.47% 810K

Health Services

| 108.1% | O: 2.34% H: 5.02% C: 3.44%
management disease test kidney

New Signatera™ MRD Data in Gastrointestinal Cancers to be Presented at the ASCO GI Symposium 2023
Published: 2023-01-19 (Crawled : 14:20) - biospace.com/
NTRA | News M | $91.47 0.47% 0.47% 810K

Health Services

| 123.28% | O: -1.54% H: 1.59% C: -1.56%
symposium gastrointestinal asco cancer

Foundation Medicine and Natera Announce the Launch of FoundationOne®Tracker Personalized Circulating Tumor DNA Monitoring Assay for Investigational Use and Early Access Clinical Use
Published: 2023-01-09 (Crawled : 13:00) - biospace.com/
NTRA | News M | $91.47 0.47% 0.47% 810K

Health Services

| 147.77% | O: 1.87% H: 1.38% C: -2.79%
foundationone tumor dna

Natera to Participate in the Piper Sandler 34th Annual Healthcare Conference
Published: 2022-11-23 (Crawled : 14:00) - biospace.com/
NTRA | News M | $91.47 0.47% 0.47% 810K

Health Services

| 158.33% | O: 0.17% H: 7.02% C: 4.93%
conference